These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 20304215)

  • 1. Influence of mycophenolate mofetil on preservation of kidney function in liver transplant patients.
    Barrera-Pulido L; Espinosa-Aguilar MD; Marín D; Nuñez-Garcia F; Jiménez-Pérez M; de la Mata-Garcia M; Gómez-Bravo MA
    Transplant Proc; 2010 Mar; 42(2):651-5. PubMed ID: 20304215
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Use of mycophenolate mofetil in liver transplantation: Andalusian Liver Registry.
    Barrera-Pulido L; Marin D; de la Mata M; López-Garrido MA; Gómez-Bravo MA; Jiménez M; Nuñez F; Noguera F
    Transplant Proc; 2009; 41(6):2177-80. PubMed ID: 19715865
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Improvement of renal function after conversion to mycophenolate mofetil combined with low-level calcineurin inhibitor in liver transplant recipients with chronic renal dysfunction.
    Ponton C; Vizcaíno L; Tomé S; Otero E; Molina E; Castroagudín JF; López-Lago A; Varo Pérez E
    Transplant Proc; 2010 Mar; 42(2):656-9. PubMed ID: 20304216
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combined mycophenolate mofetil and minimal dose calcineurin inhibitor therapy in liver transplant patients: clinical results of a prospective randomized study.
    Beckebaum S; Klein CG; Sotiropoulos GC; Saner FH; Gerken G; Paul A; Cicinnati VR
    Transplant Proc; 2009; 41(6):2567-9. PubMed ID: 19715976
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of mycophenolate mofetil combined with very low-dose cyclosporine microemulsion in long-term liver-transplant patients with renal dysfunction.
    Cantarovich M; Tzimas GN; Barkun J; Deschênes M; Alpert E; Tchervenkov J
    Transplantation; 2003 Jul; 76(1):98-102. PubMed ID: 12865793
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of combined mycophenolate mofetil and low-dose calcineurin inhibitor therapy on renal function, cardiovascular risk factors, and graft function in liver transplant patients: preliminary results of an open prospective study.
    Beckebaum S; Cicinnati VR; Klein CG; Brokalaki E; Yu Z; Malago M; Frilling A; Gerken G; Broelsch CE
    Transplant Proc; 2004 Nov; 36(9):2671-4. PubMed ID: 15621120
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical trial: switch to combined mycophenolate mofetil and minimal dose calcineurin inhibitor in stable liver transplant patients--assessment of renal and allograft function, cardiovascular risk factors and immune monitoring.
    Cicinnati VR; Yu Z; Klein CG; Sotiropoulos GC; Saner F; Malagó M; Frilling A; Gerken G; Broelsch CE; Beckebaum S
    Aliment Pharmacol Ther; 2007 Nov; 26(9):1195-208. PubMed ID: 17944734
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Introduction of mycophenolate mofetil in maintenance liver transplant recipients: what can we expect? Results of a 10-year experience.
    Dumortier J; Guillaud O; Pittau G; Salandre J; Adham M; Scoazec JY; Boillot O
    Transplant Proc; 2010 Sep; 42(7):2602-6. PubMed ID: 20832553
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Two yr mycophenolate mofetil plus low-dose calcineurin inhibitor for renal dysfunction after liver transplant.
    Biselli M; Vitale G; Gramenzi A; Riili A; Berardi S; Cammà C; Scuteri A; Morelli MC; Grazi GL; Pinna AD; Andreone P; Bernardi M
    Clin Transplant; 2009; 23(2):191-8. PubMed ID: 19210525
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mycophenolate mofetil monotherapy in patients who underwent liver transplantation for hepatitis C cirrhosis.
    Manrique A; Jiménez C; Ortega P; Abradelo M; Gimeno A; Calvo J; Cambra F; -Sterup RL; Morales JM; Moreno E
    Transplant Proc; 2008 Nov; 40(9):2962-4. PubMed ID: 19010160
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of four different immunosuppression protocols without long-term steroid therapy in kidney recipients monitored by surveillance biopsy: five-year outcomes.
    Anil Kumar MS; Irfan Saeed M; Ranganna K; Malat G; Sustento-Reodica N; Kumar AM; Meyers WC
    Transpl Immunol; 2008 Nov; 20(1-2):32-42. PubMed ID: 18773960
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunosuppression based on mycophenolate mofetil in stable liver transplanted patients.
    Bilbao I; Castells L; Rojas L; Cancino J; Dopazo C; Castro E; Pou L; Andino R; Margarit C
    Int Immunopharmacol; 2006 Dec; 6(13-14):1977-83. PubMed ID: 17161351
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Everolimus with reduced cyclosporine versus MMF with standard cyclosporine in de novo heart transplant recipients.
    Lehmkuhl HB; Arizon J; Viganò M; Almenar L; Gerosa G; Maccherini M; Varnous S; Musumeci F; Hexham JM; Mange KC; Livi U;
    Transplantation; 2009 Jul; 88(1):115-22. PubMed ID: 19584690
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical evolution in the first 3 months of patients after liver transplantation in maintenance phase converted from mycophenolate mofetil to mycophenolate sodium due to gastrointestinal complications.
    Miras M; Carballo F; Egea J; Martínez C; Alvarez-López MR; Sánchez-Bueno F; Parrilla P
    Transplant Proc; 2007 Sep; 39(7):2314-7. PubMed ID: 17889175
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunosuppression with low-dose daclizumab in liver transplant recipients with impaired kidney function: a single-center experience.
    Post M; Raszeja-Wyszomirska J; Jarosz K; Lubikowski J; Wasilewicz M; Mydłowska M; Milkiewicz P; Wójcicki M
    Transplant Proc; 2009 Oct; 41(8):3107-9. PubMed ID: 19857687
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mycophenolate mofetil for the treatment of a first acute renal allograft rejection: The Mycophenolate Mofetil Acute Renal Rejection Study Group.
    Transplantation; 1998 Jan; 65(2):235-41. PubMed ID: 9458021
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mycophenolate mofetil in combination with reduction of calcineurin inhibitors for chronic renal dysfunction after liver transplantation.
    Pageaux GP; Rostaing L; Calmus Y; Duvoux C; Vanlemmens C; Hardgwissen J; Bernard PH; Barbotte E; Vercambre L; Bismuth M; Puche P; Navarro F; Larrey D
    Liver Transpl; 2006 Dec; 12(12):1755-60. PubMed ID: 17133564
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term effects of calcineurin inhibitor conversion to mycophenolate mofetil on renal function after liver transplantation.
    Créput C; Blandin F; Deroure B; Roche B; Saliba F; Charpentier B; Samuel D; Durrbach A
    Liver Transpl; 2007 Jul; 13(7):1004-10. PubMed ID: 17600361
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Steroid-free Liver Transplantation Using Rabbit Antithymocyte Globulin Induction in 500 Consecutive Patients.
    Yoo MC; Vanatta JM; Modanlou KA; Campos L; Nezakatgoo N; Nair S; Eason JD
    Transplantation; 2015 Jun; 99(6):1231-5. PubMed ID: 25539464
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mycophenolate mofetil for the treatment of refractory, acute, cellular renal transplant rejection. The Mycophenolate Mofetil Renal Refractory Rejection Study Group.
    Transplantation; 1996 Mar; 61(5):722-9. PubMed ID: 8607174
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.